贝伐珠单抗联合XELOX化疗方案治疗转移性结直肠癌患者的效果

Effects of Bevacizumab combined with XELOX chemotherapy in patients with metastatic colorectal cancer

目的:观察贝伐珠单抗联合XELOX化疗方案治疗转移性结直肠癌患者的效果。方法:选取120例转移性结直肠癌患者为研究对象,按照随机数字表法分为对照组和研究组各60例。对照组采用XELOX化疗方案治疗,研究组在对照组基础上采用贝伐珠单抗治疗,比较两组临床疗效、治疗前后免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平、不良反应发生率和1年生存率。结果:研究组治疗总有效率为68.33%,高于对照组的50.00%,差异有统计学意义(P<0.05);治疗后,两组CD4^(+)水平和CD4^(+)/CD8^(+)均低于治疗前,但研究组高于对照组,两组CD8^(+)水平均高于治疗前,但研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);研究组1年生存率为91.67%,高于对照组的78.33%,差异有统计学意义(P<0.05)。结论:贝伐珠单抗联合XELOX化疗方案治疗转移性结直肠癌患者,可提高治疗总有效率和1年生存率,改善免疫功能,效果优于单纯XELOX化疗方案治疗。

Objective:To observe effects of Bevacizumab combined with XELOX chemotherapy in patients with metastatic colorectal cancer.Methods:120 patients with metastatic colorectal cancer were selected as the research objects and were divided into control group and study group according to the random number table method,60 cases in each group.The control group was treated with XELOX chemotherapy,while the study group was treated with Bevacizumab on the basis of that of the control group.The clinical treatment effects,the immune function index levels(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),the incidence of adverse reactions and 1-year survival rate were compared between the two groups before and after the treatment.Results:The total effective rate of the study group was 68.33%,which was higher than 50.00%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the two groups were lower than before the treatment,but those of the study group were higher than those of the control group;the CD8^(+)levels in the two groups were higher than before the treatment,but that of the study group was lower than that of the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Further,the 1-year survival rate of the study group was 91.67%,which was higher than the control group of 78.33%,and the difference was statistically significant(P<0.05).Conclusions:Bevacizumab combined with XELOX chemotherapy regimen in the treatment of the patients with metastatic colorectal cancer can improve the overall treatment effective rate and the 1-year survival rate,and improve the immune function.Moreover,it is superior to single XELOX chemotherapy.